AstraZeneca Plc (AZN.L) (AZN.N) would consider buying a company such as Juno Therapeutics Inc (JUNO.O), Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider.
Juno's shares rose as much as 14.9 percent to $61.
Seattle-based Juno, among the few companies developing a new class of immuno-oncology treatments called CAR-T cell therapies, had a market value of $4.38 billion as of Monday's close.
The companies were not immediately available to comment on the report.
AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca's cancer drugs in combination with Juno's CAR-T cell therapy, which is considered to be a breakthrough in cancer treatment.
Juno's shares rose as much as 14.9 percent to $61.
Seattle-based Juno, among the few companies developing a new class of immuno-oncology treatments called CAR-T cell therapies, had a market value of $4.38 billion as of Monday's close.
The companies were not immediately available to comment on the report.
AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca's cancer drugs in combination with Juno's CAR-T cell therapy, which is considered to be a breakthrough in cancer treatment.